FiercePharma7d
Astellas takes $760M charge, reveals slowdown for eye drug Izervay after regulatory stumbles
Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic atrophy (GA) med Izervay has taken a few beatings in recent months.
FierceBiotech8d
Astellas fires CSO and chief manufacturing officer in C-suite shake-up
Astellas is preparing a significant shake-up of its top-tier roles, including transforming its chief medical officer into a new R&D position and ushering out its current chief scientific officer ...
pharmaphorum3d
Astellas to work with Adaptimmune to develop 'off the shelf' T-cell therapies
Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer. The Japanese pharma said its wholly-owned subsidiary Universal ...
Hosted on MSN1mon
Frascos de medicinas retirados del mercado podrían tener cápsulas vacías. Esto puede causar la muerte
La medicina Prograf, del laboratorio Astellas Pharma, se receta después de trasplantes de corazón, hígado, riñones o pulmones. Por su parte, Astagraf XL, también de Astellas, se receta luego ...
Hosted on MSN9mon
Los laboratorios congelan los precios de los medicamentos por 30 días: de cuáles
La entidad que agrupa a 41 laboratorios principalmente de capitales extranjeros pero deja librado a cada firma la facultad de adherir a la iniciativa. Algunos de los laboratorios que forman parte ...